Russell Investments Group Ltd. Sells 181,338 Shares of Viridian Therapeutics, Inc. $VRDN

Russell Investments Group Ltd. lessened its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 47.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 198,258 shares of the company’s stock after selling 181,338 shares during the quarter. Russell Investments Group Ltd. owned about 0.24% of Viridian Therapeutics worth $2,673,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Deep Track Capital LP boosted its stake in shares of Viridian Therapeutics by 20.6% during the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company’s stock worth $86,701,000 after acquiring an additional 771,796 shares in the last quarter. Tang Capital Management LLC boosted its stake in shares of Viridian Therapeutics by 11.1% during the 4th quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company’s stock worth $47,789,000 after acquiring an additional 250,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Viridian Therapeutics by 2,847.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company’s stock worth $25,436,000 after acquiring an additional 1,281,799 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of Viridian Therapeutics by 155.9% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company’s stock worth $20,850,000 after acquiring an additional 662,634 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Viridian Therapeutics by 19.3% during the 4th quarter. Northern Trust Corp now owns 694,142 shares of the company’s stock worth $13,307,000 after acquiring an additional 112,534 shares in the last quarter.

Viridian Therapeutics Trading Up 6.7%

Viridian Therapeutics stock opened at $19.23 on Monday. The business has a 50 day moving average price of $16.60 and a two-hundred day moving average price of $15.09. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -5.02 and a beta of 0.42. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) EPS for the quarter, meeting the consensus estimate of ($1.00). The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The company’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.81) EPS. As a group, equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Upgrades and Downgrades

VRDN has been the subject of several recent analyst reports. Oppenheimer increased their target price on Viridian Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. Needham & Company LLC decreased their target price on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. JMP Securities decreased their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company decreased their target price on Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research note on Thursday, August 7th. Finally, The Goldman Sachs Group increased their target price on Viridian Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, August 7th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.00.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.